A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

Real World Study to Evaluate Patient and Care Partner Ratings on Early Experience of Injection and Device for KESIMPTA® (Ofatumumab) Indicated for Multiple Sclerosis

This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.

Study Overview

• Status: Completed
• Conditions: Multiple Sclerosis
• Intervention / Treatment: Other: Kesimpta

Detailed Description

The study aimed to enroll ninety-four (94) patients/care partners. The time period for enrollment was dependent on the uptake of KESIMPTA in the real-world.

Data collected for the study was obtained directly from the patient/care partner within the web-based database: De-identified data was stored on a secure server and transferred for analysis. Responses from the patient and care partner surveys were pooled for analysis of study endpoints.

• Study Type: Observational
• Enrollment (Actual): 105

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • East Hanover, New Jersey, United States, 07936
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

To ensure a representative sample of patients with MS, the patient study population will include patients who are new to the use of injectable treatments for MS, as well as those with use of other injectable MS treatments prior to initiation of KESIMPTA using the Sensoready® pen.

Patients care partner (formal or informal) may also be eligible for study participation.

Description

Patients with MS Inclusion Criteria:

• Adult aged eighteen (18) years of age or over at the time of the survey
• Prescribed KESIMPTA within the prior 12 months and currently self-administering treatment using the Sensoready® pen
• MS diagnosis based on 2017 McDonald criteria

Care Partner Inclusion Criteria:

• Adult aged eighteen (18) years of age or over
• Formal or informal care partner of patient with MS prescribed KESIMPTA within the prior 12 months
• Is currently administering KESIMPTA using the Sensoready® pen on their patient's behalf

Patients with MS Exclusion Criteria:

• Previously used injection as a part of inclusion in any ofatumumab (OMB) randomized clinical trial
• Active Hepatitis B virus (HBV)
• Cognitive impairment that would impact their ability to participate in a survey study

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Kesimpta; Patients or caregivers of patients administered Kesimpta	Other: Kesimpta; There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.; Other Names: ofatumumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of respondents in top two rating categories for device satisfaction on use of KESIMPTA Sensoready	Proportion of respondents (patients and care partners) in top two rating categories (satisfied and extremely satisfied) for device satisfaction on use of KESIMPTA Sensoready®	Up to 6 months, at the time of survey completion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients by US region of residence	Census US geographic region of residence (Northeast, Midwest, South, or West)	Up to 6 months, at the time of survey completion
Proportion of patients by educational level	Proportion of patients by educational level was collected	Up to 6 months, at the time of survey completion
Patients Determined Disease Steps (PDDS)	PDDS was used as a proxy to Expanded Disability Status Scale (EDSS). People were asked to choose one out of nine options that best describes how well they walk. 0 is "normal" and 8 is "bedridden."	Up to 6 months, at the time of survey completion
General Health	Participants were asked "How is your general health today?" and they had to choose one out of five options that best describes how well they feel from "Poor", "Fair" ,"Good", "Very Good" to "Excellent".	Up to 6 months, at the time of survey completion
Proportion of patients by Multiple Sclerosis Phenotype	Proportion of patients by Multiple Sclerosis Phenotype was collected: RRMS: Relapsing-Remitting Multiple Sclerosis; SPMS: Secondary Progressive Multiple Sclerosis	Up to 6 months, at the time of survey completion
Proportion of patients with co-morbidities	Proportion of patients with co-morbidities was collected	Up to 6 months, at the time of survey completion
Importance of healthcare provider (HCP) instructions for first injection	Participants were asked to rate their level of agreement with each statement related to their first Kesimpta injection. 1) I felt it was essential to have a healthcare provider instruct me on how to perform my first KESIMPTA injection using the Sensoready® pen, 2) I felt I needed to have a healthcare provider watch me administer my first KESIMPTA injection using the Sensoready® pen, and 3) I felt comfortable receiving instructions from my healthcare provider in the clinic on how to administer my first KESIMPTA injection using the Sensoready® pen and did not need my healthcare provider to be present to administer it at home. Participants were asked to choose five options toward each statement from "Strongly Disagree" to "Strongly Agree".	Up to 6 months, at the time of survey completion
Level of anxiety with injections, in general	Participants were asked "Using a scale of 0 to 10, 0 being Not at All Confident and 10 being Extremely Confident, how confident do you feel about your ability to administer KESIMPTA using the Sensoready® pen on your own?"	Up to 6 months, at the time of survey completion
Proportion of patients performing preparation activities for injection	Proportion of patients performing preparation activities for injection: Time to take KESIMPTA Sensoready® pen out of the refrigerator and allow it to reach room temperature prior to injection (minutes) (step A); Time to perform the injection including picking up the Sensoready® pen, injecting and disposing in the sharps container (minutes) (step B)	Up to 6 months, at the time of survey completion
Proportion of participants by site of administration	Proportion of participants by site of administration was collected: thigh; abdomen; upper outer arm	Up to 6 months, at the time of survey completion
Proportion of participants by individual medication as previous Disease Modifying Therapy (DMT)	Proportion of participants by individual medication as previous Disease Modifying Therapy (DMT) was collected among DMT experienced patients	Up to 6 months, at the time of survey completion
Proportion of patients who are DMT naïve or experienced	Proportion pf patients who are DMT naïve or experienced was collected.	Up to 6 months, at the time of survey completion
Proportion of participants by reasons for starting KESIMPTA	Proportion of participants by reasons for starting KESIMPTA was collected: ease of dosing schedule; avoidance of infusion clinics; at home convenience; enhanced efficacy and safety profile; HCP recommendation; lack of insurance coverage for other DMTs; Other	Up to 6 months, at the time of survey completion
Proportion of participants by reasons to switch from most recent therapy	Proportion of participants by reasons to switch from most recent therapy (insurance, lack of efficacy/wear off effect, side-effects and tolerability, adherence concerns etc.) was collected among DMT experienced patients.	Up to 6 months, at the time of survey completion
Proportion of patients agreeing with the attributes of the device Usability Characteristics during self-administration	Percentage of patients who agree with each attribute of the device Usability Characteristics during self-administration, based on patient self-report was collected: Overall ease of use; Device ergonomics ("feeling" in the hand ); Steps for preparing and using device; Time required for preparation and use of device; Convenience/Flexibility for travel with device	Up to 6 months, at the time of survey completion
Patient Confidence	Percentage o patients who agree with each attribute regarding confidence, based on patient self-report, was collected: Confidence to self-administer KESIMPTA using the device; Intention to continue use of device; Recommendation of KESIMPTA device use to others; Ease of KESIMPTA's monthly dosing schedule	Up to 6 months, at the time of survey completion
Overall device satisfaction by treatment duration	Overall device satisfaction. Participants choose between five options from 1: Extremely Dissatisfied, 2 Dissatisfied, 3: Neither Satisfied nor Dissatisfied, 4: Satisfied, 5: Extremely Satisfied. The higher score means a better overall devise satisfaction.	Up to 6 months, at the time of survey completion
Overall device satisfaction score of the study participants by DMT experience	Percentage of patients by overall satisfaction score (extremely dissatisfied, dissatisfied, neither satisfied nor dissatisfied, satisfied, extremely satisfied) by DMT experience	Up to 6 months, at the time of survey completion

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals
• Investigators: Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publications and helpful links

Helpful Links

• Results for COMB157GUS13 that is getting linked from the Novartis Clinical Trials Website

Study record dates

Study Major Dates

• Study Start (Actual): November 24, 2021
• Primary Completion (Actual): February 15, 2023
• Study Completion (Actual): February 15, 2023

Study Registration Dates

• First Submitted: March 21, 2022
• First Submitted That Met QC Criteria: April 12, 2022
• First Posted (Actual): April 19, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2024
• Last Update Submitted That Met QC Criteria: March 22, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Multiple Sclerosis; MS; ofatumumab; NIS; KESIMPTA
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Multiple Sclerosis; Sclerosis; Antineoplastic Agents; Ofatumumab
• Other Study ID Numbers: COMB157GUS13

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO